Cabaletta Bio Inc (CABA)
12.34
-0.28
(-2.22%)
USD |
NASDAQ |
May 17, 16:00
12.67
+0.33
(+2.67%)
After-Hours: 20:00
Cabaletta Bio Cash from Financing (TTM): 194.26M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 194.26M |
| December 31, 2023 | 187.63M |
| September 30, 2023 | 127.47M |
| June 30, 2023 | 127.38M |
| March 31, 2023 | 33.16M |
| December 31, 2022 | 32.98M |
| September 30, 2022 | 13.72M |
| June 30, 2022 | 39.06M |
| March 31, 2022 | 46.79M |
| Date | Value |
|---|---|
| December 31, 2021 | 48.90M |
| September 30, 2021 | 35.31M |
| June 30, 2021 | 10.10M |
| March 31, 2021 | 2.185M |
| December 31, 2020 | -0.024M |
| September 30, 2020 | 73.26M |
| June 30, 2020 | 71.03M |
| March 31, 2020 | 70.22M |
| December 31, 2019 | 119.92M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-0.024M
Minimum
Dec 2020
194.26M
Maximum
Mar 2024
68.52M
Average
47.85M
Median
Cash from Financing (TTM) Benchmarks
| Editas Medicine Inc | 118.23M |
| ACADIA Pharmaceuticals Inc | 24.71M |
| Alnylam Pharmaceuticals Inc | 154.67M |
| Regeneron Pharmaceuticals Inc | -1.420B |
| Vertex Pharmaceuticals Inc | -625.00M |